Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...

However, with scarce training, few region-specific guidelines, and symptoms that often mimic common eye problems, many ...

Here are four patient and professional organizations that provide information and support for people who are living with ...

Danish archaeologists uncovered 77 medieval graves in Aarhus, revealing the harsh realities of 12th-century Christian life ...

The CALM-CAH Phase 3 study is a randomized, placebo-controlled trial evaluating atumelnant in adults with classic CAH, designed to assess reductions in excess androgens, improvements in glucocorticoid ...

Immunovant ( ($IMVT) ) has issued an announcement. On December 10, 2025, Immunovant announced the pricing of an underwritten offering of its ...

Watts challenged the decision in the Personal Injury Commission and represented himself during the proceedings. EML’s case ...

Scientists remain divided over whether the human Y chromosome will eventually vanish. But clinicians say the real concern ...

"[Williams] does not have frontotemporal dementia, so that should be game, set, match," famed attorney Joe Tacopina said in ...

Archaeologists in Norway have excavated a Viking Age grave of an individual bedecked in costume and jewelry, as reported by ...

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.